A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
Recruiting
Pompe disease is a genetic condition which causes muscle weakness over time. People with Pompe disease have a faulty gene that makes an enzyme called acid alpha-glucosidase (or GAA). This enzyme breaks down a type of sugar called glycogen. Without this enzyme, there is a build-up of glycogen in the cells of the body. This causes muscle weakness and other symptoms. Pompe disease can happen at any age, but in late-onset Pompe disease, symptoms generally start from 12 months old onwards. The stand... Read More
Gender:
All
Ages:
Between 16 years and 69 years
Trial Updated:
03/14/2024
Locations: Lysosomal and Rare Diseases Research and Treatment Center, Inc., Fairfax, Virginia +3 locations
Conditions: Pompe Disease (Late-onset)
Determination of Core Body Temperature in Parturient Warmed With Upper or Underbody Forced Air Cover (Bair Hugger)
Recruiting
This study is intended to calculate the core body temperature in patients who are having a Cesarean Section (C/S) and are kept warm with an Upper Body Forced Air Warming device (Bair Hugger) or underbody forced air warmer. These warming devices are approved and are a required item in many if not all surgical procedures. They are used daily throughout the hospital. The research question is: Where is the best place to position the warming blanket in pregnant mothers undergoing Cesarean section del... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Cesarean Section
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
Recruiting
The goal of this study is to help identify the best antibiotic treatment for pregnant people when their water breaks prematurely (a condition abbreviated as PPROM). Current practice is to attempt to maintain the pregnancy until at least 34 weeks gestational age, when the risks of prematurity to the baby are lessened. Research shows that antibiotics help the pregnancy last longer, but there have been limited studies about which combination works best. Currently, both azithromycin and erythromycin... Read More
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
03/13/2024
Locations: Inova Fairfax Medical Campus, Falls Church, Virginia
Conditions: Premature Rupture of Membrane
Biomarkers Related to Bone in Pediatric Gaucher Disease
Recruiting
Aims of the observational study is to establish novel blood-based biomarkers for grading bone disease in pediatric patients with Gaucher disease (GD). Patients with clinically confirmed GD: deficient GCase enzyme activity and corresponding genetic analysis will be eligible for enrollment. Levels of Lyso-Gb1, chitotriosidase, and CCL18 will be established for future bone biomarkers correlation analysis. Skeletal involvement will be assessed using standard clinical diagnostic tools, such as skelet... Read More
Gender:
All
Ages:
Between 5 years and 21 years
Trial Updated:
03/12/2024
Locations: Lysosomal and Rare disorder research and treatment center, Fairfax, Virginia
Conditions: Gaucher Disease, Bone Diseases
Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors
Recruiting
To determine whether telemedicine is an acceptable addition to pre-operative counseling, compared to face-to-face communication alone for patients with endometrial cancer.
Gender:
Female
Ages:
All
Trial Updated:
03/08/2024
Locations: Carilion Clinic, Roanoke, Virginia
Conditions: Telemedicine, Counseling
The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)
Recruiting
The natural history study of patients with Sanfilippo disease(s) (MPS3)
Gender:
All
Ages:
Between 5 years and 99 years
Trial Updated:
03/07/2024
Locations: LDRTC, Fairfax, Virginia
Conditions: Sanfilippo Syndrome, MPS3
A Youth-Brief Tobacco Intervention (Y-BTI) for High School Youth
Recruiting
Tobacco use is increasing among youth in the U.S. However evidence for the long-term effectiveness of tobacco cessation programs for youth is limited. The current study seeks to adapt and evaluate a universal group-based Youth Brief Tobacco Intervention (Y-BTI) plus mobile phone automated text messaging (ATM) for 9th grade students. This study will use a sequential, multi-method research design beginning with qualitative roundtable discussions with 9th grade students to adapt the existing young... Read More
Gender:
All
Ages:
Between 14 years and 15 years
Trial Updated:
03/07/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Tobacco Use Cessation, Tobacco Use, Electronic Cigarette Use
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
Recruiting
The goal of this clinical trial is to evaluate the effectiveness and implementation of a pharmacist-delivered MTM (medication therapy management) approach, called QuitAid, to quitting cigarette smoking in rural Appalachia. The main questions it aims to answer are: Is QuitAid, alone or combined with other quitting tobacco treatments, effective? What makes QuitAid easy or hard to carry out? Is it cost effective? Is it easy to maintain? Treatment: All participants will be given at least 4 weeks... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Smoking Cessation, Smoking, Cigarette, Smoking Reduction, Smoking, Smoking, Tobacco, Quitting Smoking
Kerecis Case Registry for SurgiBind : Soft Tissue Reinforcement
Recruiting
Registry Objectives The overall objective of the registry is to collect quality and safety data to assess the long-term outcomes of Kerecis Omega3 SurgiBind in surgical procedures to reinforce soft tissue and prevent surgical complications. The ultimate goal of the registry is to enhance the quality of care, patient outcomes and establish a resource to facilitate the use of fish skin in preventing surgical wound dehiscence and surgical site infection.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
03/06/2024
Locations: Kerecis, Arlington, Virginia
Conditions: Surgery-Complications
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Recruiting
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with standard dose fulvestrant (Part B) or standard dose trastuzum... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: NEXT Oncology Virginia, Fairfax, Virginia
Conditions: Advanced Cancer, Breast Cancer
Sperm Video Recording Protocol
Recruiting
The purpose of this study is to obtain anonymous video clips of male semen at high magnification, to manually select out of the video spermatozoon images, and to manually classify their morphology by qualified embryologists based on the WHO Manual criteria in order to train the BAIBYS™ Fertility System. The study will enroll males attending the clinic who may elect to contribute their unused excess sample materials from semen analysis or IVF/ICSI (Intracytoplasmic sperm injection) which is a tec... Read More
Gender:
Male
Ages:
22 years and above
Trial Updated:
03/05/2024
Locations: CCRM Northern Virginia, Vienna, Virginia
Conditions: Sperm Classification
Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD)
Recruiting
The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) by assessing its safety and tolerability in subjects with OUD.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
03/04/2024
Locations: West Virginia University: Rockefeller Neuroscience Institute, Morgantown, Virginia
Conditions: Opioid-use Disorder